Zijun Y. Xu‐Monette

Author

Zijun Y. Xu‐Monette

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

Ai, W., Cao, Xin, Chiu, April, Choi, William W.L., Dunphy, Cherie H., Medeiros, L. Jeffrey, Møller, Michael B., Parsons, Ben M., Piris, Miguel A., Ponzoni, Maurilio

237

Publications

8.8K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center University Hospital of Basel Cleveland Clinic Odense University Hospital Ospedale San Bortolo

About

Zijun Y. Xu‐Monette is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, immunology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	36	2.1K
2	Cell Biology	13	13	712
3	Health Sciences	4	4	194
4	Engineering	3	3	426
5	Data Science	1	1	39

Zijun Y. Xu‐Monette

Publications

7.5K

Citations

H-Index

Page 1

	Year	Citations
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Tina Green, Ken H. Young, Carlo Visco, Journal of Clinical Oncology	2012	677
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program Shimin Hu, Zijun Y. Xu‐Monette, Alexandar Tzankov, Blood	2013	671
Breast Implant–Associated Anaplastic Large-Cell Lymphoma: Long-Term Follow-Up of 60 Patients Roberto N. Miranda, Tariq N. Aladily, H. Miles Prince, Journal of Clinical Oncology	2013	396
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study Zijun Y. Xu‐Monette, Lin Wu, Carlo Visco, Blood	2012	383
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation Davide Rossi, Valeria Spina, Clara Deambrogi, Blood	2011	374
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study Carlo Visco, Y Li, Zijun Y. Xu‐Monette, Leukemia Hematological MalignancyLymphoid NeoplasiaEngineeringComprehensive Gene ExpressionMedicine	2012	354
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study Shimin Hu, Zijun Y. Xu‐Monette, Aarthi Balasubramanyam, Blood	2013	243
LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers Haiyang Yu, Xuetian Yue, Yuhan Zhao, Nature Communications Colorectal CancersMedicineColorectal CancerCell DeathCancer Biology	2014	197
Clinical and pathological characteristics of HIV- and HHV-8–negative Castleman disease Li Yu, Meifeng Tu, Jörge E. Cortes, Blood	2017	171
Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study Carlo Visco, Alexandar Tzankov, Zijun Y. Xu‐Monette, Haematologica	2012	165

Page 1